Article
HSD3B1 genotype identifies glucocorticoid responsiveness in severe asthma.
Proceedings of the National Academy of Sciences of the United States of America - 28 Jan 2020
Zein Joe, Gaston Benjamin, Bazeley Peter, DeBoer Mark D, Igo Robert P, Bleecker Eugene R, Meyers Deborah, Comhair Suzy, Marozkina Nadzeya V, Cotton Calvin, Patel Mona, Alyamani Mohammad, Xu Weiling, Busse William W, Calhoun William J, Ortega Victor, Hawkins Gregory A, Castro Mario, Chung Kian Fan, Fahy John V, Fitzpatrick Anne M, Israel Elliot, Jarjour Nizar N, Levy Bruce, Mauger David T, Moore Wendy C, Noel Patricia, Peters Stephen P, Teague W Gerald, Wenzel Sally E, Erzurum Serpil C, Sharifi Nima
Abstract excerpt
Asthma resistance to glucocorticoid treatment is a major health problem with unclear etiology. Glucocorticoids inhibit adrenal androgen production. However, androgens have potential benefits in asthma. HSD3B1 encodes for 3β-hydroxysteroid dehydrogenase-1 (3β-HSD1), which catalyzes peripheral conversion from adrenal dehydroepiandrosterone (DHEA) to potent androgens and has a germline missense-encoding...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
